Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FOMX - Foamix Pharmaceuticals Ltd.

Previous close
2.99
0   0%

Share volume: 0
Last Updated: Fri 06 Mar 2020 06:00:00 AM CET
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
$2.99
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 35%
Dept financing 8%
Liquidity 41%
Performance 26%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$2.99
P/E Ratio 
N/A
DAY RANGE
$2.99 - $2.99
EPS 
-$1.66
52 WEEK RANGE
$1.97 - $4.84
52 WEEK CHANGE
-$28.30
MARKET CAP 
182.402 M
YIELD 
N/A
SHARES OUTSTANDING 
61.004 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$58,624,722
AVERAGE 10 VOLUME 
$662,937
AVERAGE 30 VOLUME 
$508,890
Company detail
CEO: David Domzalski
Region: US
Website: http://www.foamixpharma.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.

Recent news